Publications by authors named "Giuseppina Antonelli"
Background: The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, without main safety concerns. The aim of NeoPowER trial is to evaluate safety and efficacy of P + H + CT in a real-world population.
Methods: We retrospectively reviewed the medical records of stage II-III, HER2 + BC patients treated with NaT: who received P + H + CT (neopower group) in 5 Emilia Romagna institutions were compared with an historical group who received H + CT (control group).
Article Synopsis
- Over the past 20 years, Next-Generation Sequencing (NGS) has become increasingly useful in identifying mutations that can be targeted for treatment in medical oncology, though its use is not currently recommended for metastatic breast cancer by the ESMO.
- A study analyzed data from 101 patients with metastatic breast cancer treated at the Modena Cancer Center, focusing on identifying actionable mutations that could influence treatment plans.
- Out of the 61 patients with pathogenic mutations identified, 75% had at least one actionable mutation; nine of these patients received targeted therapies based on their NGS results, indicating potential benefits of NGS in treatment decision-making.